by Raynovich Rod | Jan 30, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2 …2/11/23…Thermo Fisher Scientific (TMO) beats again stock is up over 3% to $588 handle. Gives bullish outlook for 2023 with 7% growth to $45.3B. Full year 2022 revenue up 15% to $44.92B with EPS $23.24. Brilliant management with financial savvy...
by Raynovich Rod | Jan 23, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-2… 1/31… Good value in Pfizer (PFE) as stock near new lows with PE of 8.26 stock at $43.50. but nobody cares as boom times for COVID vaccines end.Provides Full-Year 2023 Revenue Guidance(4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS(3)...
by Raynovich Rod | Jan 17, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Rally During #JPM23 Favors Smaller Caps Bolt-On acquisitions expected to bolster product pipelines. Macro headwinds lessened with moderating inflation. Small and mid-cap biotechs provide an innovation narrative. Here are some takeaways from #JPM23:...
by Raynovich Rod | Jan 12, 2023 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 1/13/23 Bank stocks beat with BAC and JPM trading higher. Bearish sentiment eroding as ” risk-on ” mentality takes hold before earnings. Continuing with #JPM Week Notes: 6. Continuing with the healthcare trend of more focused businesses and away...
by Raynovich Rod | Jan 9, 2023 | Biopharmaceuticals
1/11/23…Update-1…Broad Rally favors large cap growth AAPL AMZN GOOGL MSFT but CPI data coming tomorrow. Healthcare stocks (XLV) lag after outperformance last year so a bit of rotation out of defensive to risk. Large cap biopharmas holding up nicely after...
by Raynovich Rod | Dec 19, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-4…1/6/23…Broad rally sparked by latest economic data anticipating weaker economy and slowing wage growth . Bond yields are down. A ‘”soft landing ‘”scenario? We are at the JPMorgan Healthcare Conference next week. Closing...
by Raynovich Rod | Dec 11, 2022 | 2021 Rayno Biopharmaceuticals Portfolio
Update-2 Powell Reiterates Need To Fight Inflation The FED raised rates 50 bpts and Powell said more rate increases are coming, ( but aren’t we getting close to the top?). Stocks ended lower,NAZ down 0.75%, with gyrations in last 30 minute of trading. It was...
by Raynovich Rod | Nov 28, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
Uncertainty Grips Markets- But December Still Looks Good Major Indices are down as of 11 am trading amid protest in China.Apple (AAPL) is down over 2% on potential production shortfall from Foxconn.The XBI is flat at thee $81 level but large caps are strong and the...
by Rod Raynovich | Nov 21, 2022 | 2021 Rayno Biopharmaceuticals Portfolio
Update-1 11/22 Broad Market Rally with all major indices up over 1%. Small cap spec stocks gain momentum, XBI up 1.38%. Energy materials and tech strong. IBB up 0.79% to $134. Bears acknowledge year end strength but still say 2023 fraught with weakening economy and...
by Raynovich Rod | Nov 15, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Update-1 11/18…Healthcare stocks had a good week with the XLV up almost 1% to $134 despite choppiness. We are still facing MACRO headwinds and the FED so stay cautious. There was good tape action in mid-cap biopharmas. Medtech is looking better with the IHI up...
